Publications by authors named "Victoria A Hinder"
Article Synopsis
- The study aimed to see if adding a special substance called α-GalCer to a cancer treatment using cells boosts T cell responses in melanoma patients.
- Researchers tested this by giving two groups of patients different types of vaccines: one with α-GalCer and one without, and measured how well their body fought the disease.
- The results will show if the vaccine with α-GalCer is better at helping the patients’ immune system recognize and attack cancer cells.
Aim: To investigate differences in survival after diagnosis with colorectal cancer (CRC) by rurality, ethnicity and deprivation.
Methods: In this retrospective cohort study, clinical records and National Collections data were merged for all patients diagnosed with CRC in New Zealand in 2007-2008. Prioritised ethnicity was classified using New Zealand Cancer Registry data; meshblock of residence at diagnosis was used to determine rurality and socioeconomic deprivation.
A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.
Cancer Immunol Immunother
February 2018
Vaccines that elicit targeted tumor antigen-specific T-cell responses have the potential to be used as adjuvant therapy in patients with high risk of relapse. However, the responses induced by vaccines in cancer patients have generally been disappointing. To improve vaccine function, we investigated the possibility of exploiting the immunostimulatory capacity of type 1 Natural killer T (NKT) cells, a cell type enriched in lymphoid tissues that can trigger improved antigen-presenting function in dendritic cells (DCs).
View Article and Find Full Text PDFAim: Colorectal cancer is one of the most common cancers, and second-leading cause of cancer-related death, in New Zealand. The PIPER (Presentations, Investigations, Pathways, Evaluation, Rx [treatment]) project was undertaken to compare presentation, investigations, management and outcomes by rurality, ethnicity and deprivation. This paper reports the methods of the project, a comparison of PIPER patient diagnoses to the New Zealand Cancer Registry (NZCR) data, and the characteristics of the PIPER cohort.
View Article and Find Full Text PDFBackground: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC).
Methods: 49 patients with previously untreated mCRC were recruited.